Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Piper Jaffray Initiates Coverage on Peregrine Pharmaceuticals Inc. at Overweight, Announces $2.50 PT

Juan Lopez, Benzinga Staff Writer
March 05, 2013 5:16 PM
+ Follow
Print
Email
Tickers: PPHM
Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS

Posted in: News, Analyst Ratings

 

Around the Web, We're Loving...

For the Fastest Financial Updates, Click Here!
Automakers may be aiming at the wrong buyers
Intelligence Chief Clapper Blasts NSA Document Leaks
Equinix, Iron Mountain Stock Hit By IRS REIT Scrutiny
Can Netflix be a Blockbuster Again?

Most Popular

Top-Performing Dividend Payers in Health Care with the Most Upside Potential (AET, ENSG, QCOR)
Yahoo's Sneaky Email Plans and Other Top Tech Stories from the First Week of June
Derby, Preakness Winners Favorites for Belmont Stakes
Apple, Sony and Samsung Lead a Month Full of Events
Top-Performing Tech Dividend Payers with the Most Upside Potential (IMOS, HMIX, STM)
India ETFs Could be a Second-Half Surprise

Related Articles (PPHM)

Afternoon Market Gainers
Morning Market Movers
Peregrine Pharma Issues Promising 11.7 Month Median Overall Survival Data in Second-Line NSCLC Patients Treated with Bavituximab
Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer
Peregrine Closes Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab

Partner Network

Posts by Juan Lopez

Get Benzinga's News Delivered Free

Benzinga Professional

Subscribe